Cervical recurrence

Herpes Simplex. There are two types of herpes simplex vims (HSV) that infect humans. Type I causes orofacial lesions and 30% of the U.S. population suffers from recurrent episodes. Type II is responsible for genital disease and anywhere from 3 x 3 x 10 cases per year (including recurrent infections) occur. The primary source of neonatal herpes infections, which are severe and often fatal, is the mother infected with type II. In addition, there is evidence to suggest that cervical carcinoma may be associated with HSV-II infection (78—80). 

Close clinical surveillance of all women taking OCs is essential they should be reexamined at least once a year. In all cases of undiagnosed persistent or recurrent abnormal vaginal bleeding, rule out malignancy. Monitor women with a strong family history of breast cancer or who have breast nodules, fibrocystic disease of the breast, cervical dysplasia, or abnormal mammograms. 

Cisplatin was first used to treat advanced cervical cancer shortly after the drug was introduced into clinical practice in the early 1970s. Although cisplatin continues to be one of the most active agents against cervical cancer, response rates are less than 30% for patients with recurrent or metastatic disease, and complete responses are rare and usually of short duration (14). 

Evaluating recurrent or residual follicular cell tumors (treated previously by thyroidectomy and radioiodine ablation) when serum thyroglobulin >10 ng/ml and 2 1 whole-body scan is negative (October 2003) Detecting pretreatment metastases in newly diagnosed cervical cancer after negative conventional imaging (January 2005)... 

At HCL/MGH in Boston, 621 patients with chordomas and low-grade chondrosarcomas of the skull base and cervical spine were treated with protons between 1975 and January 1998. For skull base tumors, with follow-up ranging from 1 to 254 months (median of 41 months), local recurrence-free survival is significantly better for chondrosarcomas than for chordomas. It is 98% at 5 years and 94% at 10 years for chondrosarcomas and 73% at 5 years and 54% at 10 years for chordomas (Fig. 17) [39]. Overall survival is also significantly better 91% vs. 80% at 5 years and 88% vs. 54% at 10 years, respectively. 

Motexafin lutetium is also in clinical trials, having completed several Phase I and II studies. The completed trials are for the photodynamic treatment of recurrent breast cancer [41,42], light-based treatment of choroidal neovascularization, [43] and the photoangioplastic reduction of atherosclerotic plaque in peripheral [19,44] and coronary arterial disease [20,45], On the basis of these studies, MLu (Antrin Phototherapy) is currently being developed for the treatment of atherosclerotic plaque. Additionally, the National Cancer Institute is testing MLu for the PDT based treatment of prostate [46,47] and cervical cancers. 

Maintenance therapy of cervical dysplasias after standard excisional or ablative therapy Cream Reduction of recurrence was achieved 329... 

In a phase-II study, 14 patients with metastatic cervical cancer or recurrent disease not eligible for surgery or radiation received bryostatin 1 50-65 pg/m -I- cisplatin 50mg/m. The most common adverse effects were myalgia, anemia, and nausea or vomiting one patient had a hypersensitivity reaction and one developed grade 3 nephrotoxicity (9). 

Harris RJ, Benveniste G. Recurrent laryngeal nerve blockade in patients undergoing carotid endarterectomy under cervical plexus block. Anaesth Intensive Care 2000 28(4) 431-3. 

MMPs also act as predictors of recurrence or metastatic risk. High preoperative serum levels of MMP-2 or MMP-3 are predictive of recurrence in patients with advanced urotheliai carcinoma. Furthermore, high levels of MMP-2 in ovarian tumor cells can predict tumor recurrence. The expression of certain MMPs is predictive of metastatic risk. For example, expression of MMP-1 is associated with lymph node metastasis in cervical and peritoneal metastasis in gastric cancer. MMP inhibition may be a therapeutic strategy for cancer. ... 

Recurrent UTIs cervical neoplasia Decreased efficacy with ... 

Touze E, Gauvrit J, Moulin T, Meder J, Bracard S, Mas J Risk of stroke and recurrent dissection after a cervical artery dissection a multicenter study. Neurology 2003 61 pp. 1347-1351. 

Positron emission tomography (PET) is currently being investigated to evaluate its usefulness in assessing primary and recurrent cervical cancer. No recommendations are available as yet. 

Various other sequences are available to answer specific queries and provide specific information as required according to tiunor stage. Cervical cancer extending beyond the cervix and recurrent tumors are associated with a significantly higher risk of... 

In patients with locally advanced or recurrent cervical cancer, it is often necessary to exclude ureteral obstruction, which can be done on transverse T2-weighted images that also serve to assess the paraaortic lymph nodes. In addition, coronal T2-weighted turbo-spin echo (TSE) sequences enable excellent evaluation for possible urinary retention and require little extra time to acquire. In addition, contrast-enhanced MR urography can be performed to exclude tumor-induced hydronephrosis. 

---